BridgeBio Recommends Continuing Phase 2 Clinical Trial of Lung Disease Treatment 'BBT-877'

Bridge Biotherapeutics announced on the 10th that it received a recommendation from the 4th Independent Data Monitoring Committee (IDMC) held on the 8th to continue the Phase 2 clinical trial of BBT-877, a candidate drug under development for idiopathic pulmonary fibrosis (IPF).

At this fourth meeting, following the 3rd IDMC held in April, experts recommended continuing the clinical trial as planned without concerns regarding the drug's safety and efficacy, consistent with previous assessments. This recommendation was based on a review of the overall efficacy and safety data of all trial subjects as of the 2nd of last month. Among the 129 subjects in the Phase 2 trial, 82 have completed the 24-week dosing procedure. Based on the results of this meeting, the company plans to accelerate the clinical trial progress, preparing for the top-line data announcement in April next year, while simultaneously focusing on commercialization through global technology licensing negotiations.

Lee Jung-kyu, CEO of Bridge Biotherapeutics, stated, “We are honored to have confirmed the safety and efficacy of the drug through a total of four expert meetings, allowing us to dedicate ourselves to innovative new drug development. With the active cooperation of global clinical researchers, patients, and related organizations, we will smoothly complete the remaining trial procedures and respond with competitive data presentations leading to prompt commercialization success.”